title: Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era.
abstract: OBJECTIVE
  To compare the postprocedural and long-term clinical outcomes of two groups of patients, all presenting with chronic saphenous vein graft (SVG) occlusion, who underwent either SVG or native vessel reopening.
  
  
  BACKGROUND
  Chronic total occlusions (CTO) treatment in patients who underwent previous surgical revascularization is a dilemma and the choice of performing native vessel or SVG recanalization is not always easy.
  
  
  METHODS
  Between July 2002 and October 2004, a total of 260 patients were successfully treated for a CTO. Of them, we selected all patients (n = 24) who had previous bypass surgery with graft occlusion. Of this final group, 13 patients underwent a percutaneous graft recanalization while 11 underwent native vessel reopening.
  
  
  RESULTS
  Primary end points were in-hospital and 3-year rates of death, myocardial infarction, target lesion revascularization, and target vessel revascularization. No events occurred in either group during the in-hospital period. Cumulative 3-year event-free survival in the native vessel and SVG group was 81.8% and 83.9% respectively (P = NS). One death and one TVR occurred in each group.
  
  
  CONCLUSIONS
  In selected cases, SVG reopening instead of the native vessel is feasible. In such a high-risk population, drug-eluting stent implantation in both SVG and native CTO lesions is associated with good long-term outcomes.
authors.affiliation: Interventional Cardiology Department, Thoraxcenter, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Meliga
authors.forename: Héctor M
authors.initials: HM
authors.lastname: García-García
authors.forename: Neville
authors.initials: N
authors.lastname: Kukreja
authors.forename: Joost
authors.initials: J
authors.lastname: Daemen
authors.forename: Shuzou
authors.initials: S
authors.lastname: Tanimoto
authors.forename: Steve
authors.initials: S
authors.lastname: Ramcharitar
authors.forename: Carlos A G
authors.initials: CA
authors.lastname: van Mieghem
authors.forename: Georgios
authors.initials: G
authors.lastname: Sianos
authors.forename: Martin
authors.initials: M
authors.lastname: van der Ent
authors.forename: Willem J
authors.initials: WJ
authors.lastname: van der Giessen
authors.forename: Pim
authors.initials: P
authors.lastname: de Feyter
authors.forename: Ron
authors.initials: R
authors.lastname: van Domburg
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D011474:Prosthesis Design; D012189:Retrospective Studies; D012501:Saphenous Vein / Q000637:transplantation*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents